IL-2-Secreting Tumor Cell Vaccines

Cytokines development have been used to treat advanced cancers, including renal cell carcinoma and melanoma with some success, but systemic administration is associated with marked toxicity. Recombinant cytokines expressed by modified tumor cells can be used to target the cytokine to tumor or vaccination sites where they can induce a proinflammatory environment, with the additional benefit of lowering the levels of circulating cytokine and therefore circumventing the toxicity related to high systemic doses. Creative Biolabs is a world leader in the field of cancer vaccine development. We developing a range of cytokines, of which IL-2 has been shown to have potential in allogeneic tumor cell vaccination models. With our extensive experience and advanced platform, we are therefore confident in offering the best services and the finest results for our customers all over the world.

Interleukin 2 (IL-2)

Interleukin 2 is produced by CD4⁺ T cells of the TH1 type. It supports recruitment, differentiation, and proliferation of T and NK cells and is frequently used systemically for the treatment of renal cell carcinoma and metastatic melanoma.

IL-2-Secreting Tumor Cell Vaccines

In autologous IL-2-secreting cell vaccination models, there is a requirement for CD8⁺ T cells and/or NK cells to establish effective protection against tumor challenge. In a study, where allogeneic cell vaccines are shown to be protective against tumor challenge in a prophylactic treatment model, IL-2-secreting vaccine is more effective than unmodified cells. Furthermore, vaccination with IL-2-secreting allogeneic cells gave rise to a cytotoxic response that recognized syngeneic tumor.

It is also shown that a mixture of IL-2-secreting autologous cells and allogeneic cells gave complete protection in a therapeutic model. In human studies, limited immunologic responses have been demonstrated after IL-2-modified allogeneic cell vaccination. Two studies in melanoma patients showed that CD8⁺ T cell responses could be mounted against vaccine cells in a small proportion of the patients. Another study demonstrated that IgG responses could be stimulated using the allogeneic melanoma cell line Mel 4932. These sera stained autologous tumor and could elicit ADCC responses against Mel 4932, although no killing of autologous tumor was seen. Trials using allogeneic IL-2-secreting tumors have generally been clinically disappointing. However, one notable study showed clinical benefit when patients were vaccinated with a mixture of allogeneic IL-2-secreting cells and autologous cells. Of 30 patients with metastatic RCC, objective responses were seen in 14 (1 complete response, 4 partial responses, 9 with stable disease). There was improved median survival in the vaccination group compared to control subjects.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.